Application of siglec7 as immunotherapy target in multiple myeloma and monoclonal antibody thereof

By developing a monoclonal antibody targeting Siglec7 and combining it with a CD38 antibody, the problems of immune escape and drug resistance in patients with multiple myeloma have been solved, the anti-tumor effect of NK cells has been enhanced, and more accurate prognostic assessment and treatment effects have been achieved.

CN122168753APending Publication Date: 2026-06-09THE SECOND AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
THE SECOND AFFILIATED HOSPITAL OF ANHUI MEDICAL UNIV
Filing Date
2026-01-31
Publication Date
2026-06-09

AI Technical Summary

Technical Problem

In the current technology, the problems of immune escape and drug resistance relapse in patients with multiple myeloma (MM) have not been effectively solved. Existing treatment methods have not been able to directly target the inhibitory checkpoint Siglec7 of NK cells, resulting in limited efficacy of immunotherapy.

Method used

A monoclonal antibody specifically targeting human Siglec7 was developed. By blocking the interaction between sialyl glycan on the surface of tumor cells and Siglec7 on NK cells, the inhibition of NK cells was relieved, and their natural killer function was enhanced. A combined strategy of anti-Siglec7 antibody and anti-CD38 antibody was proposed.

Benefits of technology

It provides more precise prognostic and diagnostic assessment tools, directly reverses NK cell function inhibition, enables more refined patient stratification management, and significantly enhances the anti-tumor effect of NK cells, breaking through the efficacy ceiling of existing therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122168753A_ABST
    Figure CN122168753A_ABST
Patent Text Reader

Abstract

The present application provides a set of complete innovative technical solutions from target discovery to treatment intervention for the immune escape and drug resistance recurrence problems existing in the clinical treatment of multiple myeloma (MM). It is found that Siglec7 is mainly highly expressed on the surface of NK cells, and the proportion and expression intensity of Siglec7 positive NK cells are significantly higher than those of complete remission and non-tumor controls; further, Siglec7 monoclonal antibody is prepared, and when the anti-Siglec7+CD38 monoclonal antibody (such as daratumumab) is used, a significant synergistic anti-tumor effect can be produced in vitro and in vivo. The technical solution completely constructs the research and development chain of "marker discovery-target verification-drug development-treatment application", and provides a new target, specific antibody drug and innovative combined drug regimen for the precise diagnosis, prognosis and especially immunotherapy of refractory and relapsed patients with multiple myeloma, which has great clinical transformation value and market prospect.
Need to check novelty before this filing date? Find Prior Art